# Metastatic Nasopharyngeal Carcinoma

> **NCT06886347** · PHASE1 · RECRUITING · sponsor: **Chen Xiaozhong** · enrollment: 47 (estimated)

## Conditions studied

- Metastatic Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Penplimab Injection
- **DRUG:** Antitinib Hydrochloride Capsules
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT06886347
- **Lead sponsor:** Chen Xiaozhong
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-07
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06886347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06886347, "Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06886347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*